Middle East Pharmaceutical Industries Co. Announces the formation of its Audit Committee.

Element List	Explanation
Introduction	Middle East Pharmaceutical Industries Co. Announces the formation of its Audit Committee for the Board term starting on 16 April 2026 (corresponding to 29 Shawal 1447 AH), based on the Board of Directors resolution dated 16-04-2026 The Committee will consist of the following members:

Element List	Explanation
Appointed Member Name	Faisal Sulaiman AlJaman
Membership Start Date	2026-04-16 Corresponding to 1447-10-28
Brief Resume of the Appointed Member	Current Positions

• Chairman of the Audit and Compliance Committee, Middle East Pharmaceutical Industries (Avalon Pharma).

• Board Member, Chairman of the Audit Committee Al-Essaiey Cars Company.

• Board Member, Chairman of the Audit Committee Arabian Tiles Company.

• CEO, Tawkeelat Finance Company.

Previous Positions

• CEO, United Cars Company

• General Manager, Al-Ahlia Advanced Systems

Academic Qualifications

• Bachelor’s degree in Computer Technology from Brunel University, United Kingdom, 1978. The date of the approval by other official authorities N/A

Element List	Explanation
Appointed Member Name	Omar Mohammed-Saeb AlJaroudi
Membership Start Date	2026-04-16 Corresponding to 1447-10-28
Brief Resume of the Appointed Member	Current Positions

• Board Member, Chairman of the Nominations and Remuneration Committee, and Member of the Audit Committee, Middle East Pharmaceutical Industries.

• Board Member, Wadi Hanifa Real Estate Development Company (WAHA).

• Board Member, Home House (London).

• Board Member, Home Grown Club (London).

• Board Member, Albani Real Estate Development Company.

Previous Positions

• Board Member, Shuaa Capital Saudi Arabia,

• Chairman, Shuaa Capital Hospitality (Shuaa Hospitality Fund).

• Board Member Rymco Company (outside KSA).

• Board Member, Admic Company (outside KSA).

• Board Member, Achrafieh (outside KSA).

• Board Member Actionnaires Unis (outside KSA).

• Board member Blink Experience

Academic Qualifications

• Master’s degree in Economics from Syracuse University, New York, USA, 1984.

• Bachelor’s degree in Business Administration from the American University of Beirut, Lebanon, 1983.

• CME1 Certificate (Securities Trading) from the Financial Academy, Riyadh, 2013. The date of the approval by other official authorities N/A

Element List	Explanation
Appointed Member Name	Yanal Mwaffaq Soudi
Membership Start Date	2026-04-16 Corresponding to 1447-10-28
Brief Resume of the Appointed Member	Current Positions

• Member of the Audit Committee – Avalon Pharma

• Audit Committee Member – Arabian Centers Company (Cenomi Center)

• Audit Committee Member – Saudi Reinsurance Company.

• Chairman of the Audit Committee – National Finance Company,

• Chairman of the Audit Committee – Rafal Real Estate Development Company.

• Board Member and Chairman of the Audit Committee – Baan Holding Group.

• Chairman of the Audit Committee – Al-Maghrabi Hospitals & Centers.

Previous Positions

• Member of the Advisory Partners – Europe & Middle E& Y.

• Head of Audit Services Department Riyadh – E& Y.

• Head of Independence (Risk Management) Department – Middle

• East & North Africa – E& Y.

• Board Member, Chairman of the Governance Committee – Jordan Government Investments Company,

• Board Member, Audit Committee Member, and Nominations & Remuneration Committee Member Tarfa Al-Ibda’a Company for Exhibitions & Event Management.

• Member of the Nominations & Remuneration Committee – Avalon Pharma

Academic Qualifications

• Bachelor’s degree in business administration from University of Oklahoma, United States, 1985.

• Certified Public Accountant (CPA) from the United States Board of Accountancy, 1992. The date of the approval by other official authorities N/A

Element List	Explanation
Date of Board Meeting in which Appointed New Member(s) were Appointed	2026-04-16 Corresponding to 1447-10-28
Additional Information	None.

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.